Poria in Fuling Zexie decoction for treating metabolic dysfunction-associated steatotic liver disease: Underlying mechanisms and key bioactive substances
Xing-Xin Yang, Jie Yu, Wei-Dong Chen, Yue Zhang, Yan-Yan Wang, Qi-Di Zhou, Yan-Mei Tang, Peng-Quan Wang, Huan Yang, Di-Hong Gong, Yu-Xuan Tao
Yu-Xuan Tao, Di-Hong Gong, Huan Yang, Peng-Quan Wang, Yan-Mei Tang, Qi-Di Zhou, Jie Yu, Xing-Xin Yang, College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Yunnan Key Laboratory of Southern Medicine Utilization, Kunming 650500, Yunnan Province, China
Yan-Yan Wang, Yue Zhang, Wei-Dong Chen, School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, Anhui Province, China
Co-first authors: Yu-Xuan Tao and Di-Hong Gong.
Co-corresponding authors: Jie Yu and Xing-Xin Yang.
Author contributions: Tao YX and Gong DH contributed to writing-original draft, methodology, and they contributed equally to this manuscript and are co-first authors; Tao YX contributed to investigation; Tao YX, Tang YM, Zhou QD, Wang YY, Zhang Y, and Yang XX contributed to writing - review and editing; Gong DH and Yang H contributed to visualization; Yang H contributed to formal analysis; Wang PQ contributed to software and data curation; Chen WD, Yu J, and Yang XX contributed to project administration and funding acquisition; Yu J and Yang XX contributed equally to this manuscript and are co-corresponding authors. All authors approved the final manuscript.
AI contribution statement: No AI tools have been used in the preparation, drafting, data analysis, or revision of this manuscript.
Institutional review board statement: All human cell experiments were performed using authenticated commercial cell lines, and no human-derived biological samples were obtained. Our Institutional Ethics Committee granted an institutional review board waiver for this study.
Institutional animal care and use committee statement: Approval was obtained from the Ethical Committee on Animal Care and Experimentation of the Yunnan University of Chinese Medicine (Approval No. R-062023206).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: All data used to support the findings of this study are available from the corresponding author upon reasonable request.
Corresponding author: Xing-Xin Yang, College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Yunnan Key Laboratory of Southern Medicine Utilization, No. 1076 Yuhua Road, Kunming 650500, Yunnan Province, China.
yxx78945@163.com
Received: April 9, 2026
Revised: May 10, 2026
Accepted: June 2, 2026
Published online: July 27, 2026
Processing time: 110 Days and 0.2 Hours
